A

Autolus Therapeutics plc
D

AUTL

1.95500
USD
-0.07
(-3.46%)
Post Trading·1.96000USD+0.00500(+0.26%)
حجم التداول
53,861
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
520,347,766
المقالات
المزيد

العنوان: Autolus Therapeutics plc

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3,AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.